To Evaluate Efficacy of Ashwagandhadi Churna in the Management of Tamak Shwasa
- Conditions
- Other and unspecified asthma. Ayurveda Condition: TAMAKASVASAH,
- Registration Number
- CTRI/2025/04/084547
- Lead Sponsor
- Parul Institute of Ayurved
- Brief Summary
Bronchial Asthma is a chronic inflammatory disorder of the airways involving various cells and cellular components. This inflammation causes airway hyper-responsiveness, leading to repeated episodes of wheezing, breathlessness, chest tightness, and coughing, especially during the night or early morning. Over the past few decades, the prevalence of asthma has increased, affecting individuals of all age groups. It is now recognized as a major contributor to global disability. While genetics play a role in the development and progression of asthma, the rapid rise in its prevalence points to the significant influence of environmental factors. A key feature of asthma is airway hyper-reactivity, where the airways respond excessively to harmless triggers. The loss of immune tolerance to inhaled allergens is considered a leading cause of asthma, resulting in an abnormal immune response. In Ayurveda, Bronchial Asthma is correlated with Tamaka Shwasa, a chronic disorder of the pranavaha srotas that disturbs daily activities with symptoms like cough and difficulty in breathing. Tamaka Shwasa is identified as a Swatantra Vyadhi with distinct causes and treatments. Classical texts describe it as a palliative or difficult-to-cure disease, requiring proper management and lifestyle adaptations. Pathologically, Tamaka Shwasa occurs due to an imbalance of Kapha and Vata doshas, often triggered by cold, dry food or seasonal changes, leading to airway obstruction. Ayurvedic formulations like Ashwagandhadi churna help in managing the condition by pacifying Vata and removing Kapha-induced blockages in the airways. Globally, asthma affects around 300 million people, with numbers expected to rise to 400 million by 2025. It is more prevalent in males, with a 2 to 1 male to female ratio. Asthma remains a major health concern, particularly in low and middle income countries, contributing to high treatment costs and productivity losses.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 50
Patients diagnosed with well controlled and partly controlled Bronchial Asthma as per GINA 2024 Guideline of Bronchial Asthma Patients with Prebronchodilator FEV1 of Greater than 60 Percentage of the predicted value Patient willing to sign the informed consent and can participate in the study procedure.
- Pregnant or lactating women Known cases of Diabetes, uncontrolled hypertension, heart disease, secondary severe infections, Pleural effusion, pneumonia and pneumothorax, etc.
- Uncontrolled Bronchial Asthma as per GINA Guidelines 2024 Severe Bronchial Asthma as per GINA Guidelines 2024 Patients with Prebronchodilator FEV1 Less than 60 Percentage of the predicted value History of upper or lower respiratory tract infection, within the previous 30 days History of lung resection of more than one full lobe Have a known sensitivity to formoterol, ipratropium, and salbutamol etc medicine Immunocompromised status such as HIV, tuberculosis, cancer, etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess Immunomodulatory and Bronchodilator effect of Ashwagandhadi Churna in the managemnet of Bronchial Asthma on the basis of spirometry of GINA Guidelines 2024 Spirometry-On Screening visit and 60th day
- Secondary Outcome Measures
Name Time Method To assess Immunomodulatory and Bronchodilator effect of Ashwagandhadi Churna in the managemnet of Bronchial Asthma on the basis of IgE,WBC and Asthma Control Quiestionnaire IgE-On Screening visit and 60th day
Trial Locations
- Locations (1)
Parul Ayurved Hospital
🇮🇳Vadodara, GUJARAT, India
Parul Ayurved Hospital🇮🇳Vadodara, GUJARAT, IndiaDr Stuti ParmarPrincipal investigator9662665700parmarstuti05@gmail.com